Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.32 |
| ▸ | KDR | P35968 | 4/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21828795 | 0.83 | ABL1 (0.35) | LPLLIPGPDGFRBKDR | |
| SCHEMBL13016581 | 0.83 | NOS3 (0.35) | LPLLIPGNOS3NOS1NOS2 | |
| SCHEMBL13089602 | 0.81 | NOS3 (0.47) | NOS3NOS1NOS2PDGFRBKDR | |
| SCHEMBL30736300 | 0.81 | NOS3 (0.47) | NOS3NOS1NOS2PDGFRBKDR | |
| SCHEMBL2934443 | 0.80 | PIK3R1 (0.38) | — | |
| SCHEMBL5036984 | 0.80 | LPL (0.34) | LPLLIPGEGFRCXCR2JAK2 | |
| SCHEMBL29597659 | 0.80 | EGFR (0.36) | LPLLIPGEGFRCXCR2JAK2 | |
| SCHEMBL2818121 | 0.80 | NOS3 (0.33) | NOS3NOS1NOS2PDGFRBKDR | |
| SCHEMBL16535156 | 0.80 | EGFR (0.36) | LPLLIPGEGFRCXCR2JAK2 | |
| Hydrochloric Acid SCHEMBL29960928 | 0.80 | NOS3 (0.46) | NOS3NOS1NOS2PDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20240124467-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4263542-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | Biomea Fusion, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022133064-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20140309221-A1 | METHOD OF INHIBITING HAMARTOMA TUMOR CELLS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309221-A1 | METHOD OF INHIBITING HAMARTOMA TUMOR CELLS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309221-A1 | METHOD OF INHIBITING HAMARTOMA TUMOR CELLS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| EP-2673268-A1 | METHOD OF INHIBITING HAMARTOMA TUMOR CELLS | Dana-Farber Cancer Institute, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-1984350-B1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-08-18 | — | — | EP | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| EP-1989201-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1984350-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, STAT1, STAT5B | LPL 1257/4885LIPG 865/4885NOS3 884/4885 |
| US-20240124467-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | LPL 4626/4885LIPG 4664/4885NOS3 4760/4885 |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | LPL 1484/4885LIPG 765/4885NOS3 3538/4885 |
| US-20140309221-A1 | METHOD OF INHIBITING HAMARTOMA TUMOR CELLS | PHPT1, VHL, SDHA | LPL 4236/4885LIPG 4749/4885NOS3 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.